Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Unfavorable Prognostic Value of IKAROS but Not CRLF2 in Children with BCRABL1- positive Acute Lymphoblastic Leukemia,

Arian Van Der Veer, Marieke E. Willemse, Valerie De Haas, Anjo J.P. Veerman, Willem A. Kamps, Rob Pieters, Monique L. Den Boer

Blood (2011) 118 (21): 3528.

https://doi.org/10.1182/blood.V118.21.3528.3528

Published: 2011

Journal Articles

Vascular Morphology Differences In Acute Myeloid Leukemia Are Associated with Blast Derived VEGFA Levels

Alida C. weidenaar, Ajra ter Elst, PhD, Gineke Koopmans-Klein, Stefano Rosati, MD, Wilfred F.A. den Dunnen, MD, PhD, Tiny G.J. Meeuwsen-de Boer, Willem A. Kamps, MD, PhD, Edo Vellenga, MD, PhD, Evelina S.J.M. de Bont, MD, PhD

Blood (2010) 116 (21): 2712.

https://doi.org/10.1182/blood.V116.21.2712.2712

Published: 2010

Journal Articles

High VEGFC expression is associated with unique gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid leukemia

Hendrik J. M. de Jonge, Peter J. M. Valk, Nic J. G. M. Veeger, Arja ter Elst, Monique L. den Boer, Jacqueline Cloos, Valérie de Haas, Marry M. van den Heuvel-Eibrink, Gertjan J. L. Kaspers, Christian M. Zwaan, Willem A. Kamps, Bob Löwenberg, Eveline S. J. M. de Bont

Blood (2010) 116 (10): 1747–1754.

https://doi.org/10.1182/blood-2010-03-270991

Published: 2010

Includes: Supplemental data

Journal Articles

VEGFC Predicts Poor Outcome in Pediatric as Well as Adult Acute Myeloid Leukemia: Insights in Associated Gene Expression Profiles.

Hendrik JM de Jonge, Peter Valk, PhD, Kim R Kampen, Arja ter Elst, PhD, Gertjan Kaspers, MD, PhD, Jacqueline Cloos, PhD, C. Michel Zwaan, MD, PhD, Marry M van den Heuvel-Eibrink, MD, PhD, Willem A. Kamps, MD, PhD, Ruud Delwel, PhD, Bob Lowenberg, MD, PhD, Eveline S de Bont, MD, PhD

Blood (2009) 114 (22): 997.

https://doi.org/10.1182/blood.V114.22.997.997

Published: 2009

Journal Articles

Kinome Profiling in Acute Myeloid Leukemia as a New Approach for Target Discovery.

Arja ter Elst, Maikel P Peppelenbosch, Sander H Diks, Rob Ruijtenbeek, Piet J Boender, Rik de Wijn, Frank J.G. Scherpen, Willem A Kamps, Evelina S De Bont

Blood (2008) 112 (11): 1201.

https://doi.org/10.1182/blood.V112.11.1201.1201

Published: 2008

Journal Articles

The Role of VEGFA in Malignant Progression in AML

Alida C Weidenaar, Arja ter Elst, Henk-Marijn de Jonge, Tiny Meeuwsen-de Boer, Willem A Kamps, Evelina S De Bont

Blood (2008) 112 (11): 203.

https://doi.org/10.1182/blood.V112.11.203.203

Published: 2008

Journal Articles

Addition of PTK787/ZK 222584 Can Lower the Dosage of Amsacrine To Achieve Equal Amounts of AML Cell Death.

Alida C. Weidenaar, Hendrik J.M. de Jonge, Vaclav Fidler, PhD, Arja ter Elst, PhD, Tiny Meeuwsen, Jenny Douwes, Jessica C.A. Bouma, PhD, Karel Hählen, MD/PhD, Willem A. Kamps, MD/PhD, Evelina S. de Bont, MD/PhD

Blood (2007) 110 (11): 4199.

https://doi.org/10.1182/blood.V110.11.4199.4199

Published: 2007

Journal Articles

AML1/RUNX1, One of the Most Common Targets of Aberration in Acute Myeloid Leukemia as a Transcriptional Regulator of Vascular Endothelial Growth Factor (VEGFA).

Arja ter Elst, PhD, Bin Ma, Frank Scherpen, Bart-Jan A.T. Wierenga, Jan Jacob Schuringa, PhD, Jenny Douwes, Willem A. Kamps, MD/PhD, Evelina S. de Bont, MD/PhD

Blood (2007) 110 (11): 1618.

https://doi.org/10.1182/blood.V110.11.1618.1618

Published: 2007

Journal Articles

The Cryptic Chromosomal Deletion, del(11)(p12p13), as a New Activation Mechanism of LMO2 in Pediatric T-Cell Acute Lymphoblastic Leukemia.

Pieter Van Vlierberghe, Martine van Grotel, H. Berna Beverloo, Charles Lee, Tryggvi Helgason, Jessica Buijs-Gladdines, Monique Passier, Elisabeth R. van Wering, Anjo J.P. Veerman, Willem A. Kamps, Jules P.P. Meijerink, Rob Pieters

Blood (2006) 108 (11): 220.

https://doi.org/10.1182/blood.V108.11.220.220

Published: 2006

Journal Articles

Endogenous VEGF-C mRNA Expression Increases In Vitro Drug Resistance of Pediatric AML Cells and Is an Independent Prognostic Factor for the Time To Reach Complete Remission in AML.

Hendrik J.M. de Jonge, Arja ter Elst, PhD, H. Marike Boezen, PhD, Alida C. Weidenaar, Frank J.G. Scherpen, Jessica C.A. Bouma-ter Steege, PhD, Gertjan J.L. Kaspers, MD/PhD, Bianca F. Goemans, MD, Ursula Creutzig, MD/PhD, Willem A. Kamps, MD/PhD, Evelina S.J.M. de Bont, MD/PhD

Blood (2006) 108 (11): 838.

https://doi.org/10.1182/blood.V108.11.838.838

Published: 2006

Journal Articles

The cryptic chromosomal deletion del(11)(p12p13) as a new activation mechanism of LMO2 in pediatric T-cell acute lymphoblastic leukemia

Pieter Van Vlierberghe, Martine van Grotel, H. Berna Beverloo, Charles Lee, Tryggvi Helgason, Jessica Buijs-Gladdines, Monique Passier, Elisabeth R. van Wering, Anjo J. P. Veerman, Willem A. Kamps, Jules P. P. Meijerink, Rob Pieters

Blood (2006) 108 (10): 3520–3529.

https://doi.org/10.1182/blood-2006-04-019927

Published: 2006

Journal Articles

High Expression of Multidrug Resistance-Associated Proteins Predicts Prognosis in Acute Lymphoblastic Leukemia in Children and Adults.

Sabine L.A. Plasschaert, M.D., Eveline S.J.M. de Bont, M.D. Ph.D., Marike Boezen, Ph.D., Dorina M. van der Kolk, Ph.D., Simon M.J.G. Daenen, M.D. Ph.D., Klaas Nico Faber, Ph.D., Willem A. Kamps, M.D. Ph.D., Elisabeth G.E. de Vries, M.D. Ph.D., Edo Vellenga, M.D. Ph.D.

Blood (2004) 104 (11): 1178.

https://doi.org/10.1182/blood.V104.11.1178.1178

Published: 2004

Journal Articles

Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL

Marja J. Willemse, Taku Seriu, Klaudia Hettinger, Elisabetta d'Aniello, Wim C. J. Hop, E. Renate Panzer-Grümayer, Andrea Biondi, Martin Schrappe, Willem A. Kamps, Guiseppe Masera, Helmut Gadner, Hansjoerg Riehm, Claus R. Bartram, Jacques J. M. van Dongen

Blood (2002) 99 (12): 4386–4393.

https://doi.org/10.1182/blood.V99.12.4386

Published: 2002

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Unfavorable Prognostic Value of IKAROS but Not CRLF2 in Children with BCRABL1- positive Acute Lymphoblastic Leukemia,

Vascular Morphology Differences In Acute Myeloid Leukemia Are Associated with Blast Derived VEGFA Levels

High VEGFC expression is associated with unique gene expression profiles and predicts adverse prognosis in pediatric and adult acute myeloid leukemia

VEGFC Predicts Poor Outcome in Pediatric as Well as Adult Acute Myeloid Leukemia: Insights in Associated Gene Expression Profiles.

Kinome Profiling in Acute Myeloid Leukemia as a New Approach for Target Discovery.

The Role of VEGFA in Malignant Progression in AML

Addition of PTK787/ZK 222584 Can Lower the Dosage of Amsacrine To Achieve Equal Amounts of AML Cell Death.

AML1/RUNX1, One of the Most Common Targets of Aberration in Acute Myeloid Leukemia as a Transcriptional Regulator of Vascular Endothelial Growth Factor (VEGFA).

The Cryptic Chromosomal Deletion, del(11)(p12p13), as a New Activation Mechanism of LMO2 in Pediatric T-Cell Acute Lymphoblastic Leukemia.

Endogenous VEGF-C mRNA Expression Increases In Vitro Drug Resistance of Pediatric AML Cells and Is an Independent Prognostic Factor for the Time To Reach Complete Remission in AML.

The cryptic chromosomal deletion del(11)(p12p13) as a new activation mechanism of LMO2 in pediatric T-cell acute lymphoblastic leukemia

High Expression of Multidrug Resistance-Associated Proteins Predicts Prognosis in Acute Lymphoblastic Leukemia in Children and Adults.

Detection of minimal residual disease identifies differences in treatment response between T-ALL and precursor B-ALL

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only